

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **VOLUNTARY ANNOUNCEMENT**

This is a voluntary announcement made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “Company”).

Reference is made to the disclosure of the Company in relation to the extraordinary general meeting convened by Guangzhou Wang Lao Ji Pharmaceutical Company Limited (“Wang Lao Ji”) for the purpose of considering and approving the resolutions in relation to the proposal of the advanced distribution of dividends to natural persons shareholders and the entry into of a new 10-year joint venture contract of Wang Lao Ji and the relevant voluntary announcements, details of which were set out in the announcements of the Company dated 26 June 2014 and 8 July 2014.

The Company learnt from Wang Lao Ji that it has received a subpoena of “(2014) Sui Zhong Fa Min Si Chu Zi Di No.57 ((2014) 穗中法民四初字第57號)” from the Intermediate People’s Court of Guangzhou, Guangdong Province (the “Court”). The Court will hold hearings regarding the disputes in respect of the dissolution of Wang Lao Ji at 9:00 a.m. on 23 October 2014.

Regarding to Wang Lao Ji, the Company made statement as below:

1. Upon the establishment of Wang Lao Ji, it was agreed in the joint venture contract entered into by the joint venture parties that the duration of Wang Lao Ji can be extended unless all the joint venture parties unanimously agree to terminate the joint venture. The Company will endeavour to the works to ensure the continuing operation of Wang Lao Ji in accordance with relevant laws and regulations;
2. The trademark uses by Wang Lao Ji for the production of green-box “Wang Lao Ji” herbal tea is the trademark which the controlling shareholder of the Company, Guangzhou Pharmaceutical Holdings Limited (“GPHL”), has authorized Wang Lao Ji to use. The ownership of the trademark belongs to GPHL;

3. Wang Lao Ji is a joint venture of the Company and whose principal product is Greenbox “Wang Lao Ji” herbal tea. The Company’s recognized proceeds from investing in Wang Lao Ji represented approximately 2.62% of the total profit of the Company for 2013. The investment in Wang Lao Ji will not have a significant impact on the Company’s performance.

The Company will closely monitor the progress of the event and will perform its disclosure obligations on a timely basis in accordance with relevant rules and regulations.

The Company wishes to inform the investors that the Company’s designated media for publication of its information include Shanghai Securities News (上海證券報), Securities Times (證券時報), China Securities Journal (中國證券報), Securities Daily (證券日報), the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to take due care in investment and be aware of the relevant risks.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 11 July 2014

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Fang Shuting and Mr. Chu Xiaoping as independent non-executive directors.*